Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

References

• Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann. NY Acad. Sci. 998, 407–412 (2003).
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 8(5), 475–490 (2009).
   PubMed Web of Science ®Google Scholar
• Drachman DB. Myasthenia gravis. N. Engl. J. Med. 330(25), 1797–1810 (1994).
   PubMed Web of Science ®Google Scholar
• Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180(4088), 871–872 (1973).
   PubMed Web of Science ®Google Scholar
• Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7(3), 365–368 (2001).
   PubMed Web of Science ®Google Scholar
• McConville J, Farrugia ME, Beeson D et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55(4), 580–584 (2004).
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131(Pt 7), 1940–1952 (2008).
   PubMed Web of Science ®Google Scholar
• Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J. Neurol. 247(5), 369–375 (2000).
   PubMed Web of Science ®Google Scholar
• Drachman DB, Adams RN, Stanley EF, Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 43(7), 601–610 (1980).
   PubMed Web of Science ®Google Scholar
• Toyka KV, Drachman DB, Griffin DE et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296(3), 125–131 (1977).
   PubMed Web of Science ®Google Scholar
• Lefvert AK. Immunoglobulins in myasthenia gravis. Kinetic properties of the acetylcholine-receptor antibody studied during lymph drainage. Clin. Exp. Immunol. 34(1), 111–117 (1978).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28(3), 266–272 (1978).
   PubMed Web of Science ®Google Scholar
• Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin. Immunol. Immunopathol. 7(1), 36–43 (1977).
   PubMedGoogle Scholar
• Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl Acad. Sci. USA 77(2), 755–759 (1980).
   PubMed Web of Science ®Google Scholar
• Gomez AM, Van Den Broeck J, Vrolix K et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43(5–6), 353–370 (2010).
   PubMed Web of Science ®Google Scholar
• Willcox N, Leite MI, Kadota Y et al. Autoimmunizing mechanisms in thymoma and thymus. Ann. NY Acad. Sci. 1132, 163–173 (2008).
   PubMed Web of Science ®Google Scholar
• Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann. Neurol. 22(2), 212–222 (1987).
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Brown LR, Colby TV, Harper CM Jr, Coles DT. Thymoma. Mayo Clin. Proc. 68(11), 1110–1123 (1993).
   PubMed Web of Science ®Google Scholar
• Aarli J. Myasthenia gravis and thymoma. In: Handbook of Myasthenia Gravis and Myasthenic Syndromes. Lisak RP (Ed.). Marcel Dekker, Inc., NY, USA, 207–224.
   Google Scholar
• Heidenreich F, Vincent A, Willcox N, Newsom-Davis J. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 38(11), 1784–1788 (1988).
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Aarli JA, Matre R. Myasthenia gravis: the specificities of skeletal muscle and thymus antibodies. Acta Neurol. Scand. 68(5), 328–336 (1983).
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka KV. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 36(5), 618–621 (1986).
   PubMed Web of Science ®Google Scholar
• Melms A, Schalke BC, Kirchner T, Müller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81(3), 902–908 (1988).
   PubMed Web of Science ®Google Scholar
• Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann. Neurol. 28(3), 312–319 (1990).
   PubMed Web of Science ®Google Scholar
• Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 41(8), 1270–1276 (1991).
   PubMed Web of Science ®Google Scholar
• Mygland A, Vincent A, Newsom-Davis J et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch. Neurol. 57(4), 527–531 (2000).
   PubMedGoogle Scholar
• Kadota Y, Okumura M, Miyoshi S et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin. Exp. Immunol. 121(1), 59–68 (2000).
   PubMed Web of Science ®Google Scholar
• Scarpino S, Di Napoli A, Stoppacciaro A et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 149(3), 504–512 (2007).
   PubMed Web of Science ®Google Scholar
• Ströbel P, Rosenwald A, Beyersdorf N et al. Selective loss of regulatory T cells in thymomas. Ann. Neurol. 56(6), 901–904 (2004).
   PubMed Web of Science ®Google Scholar
• Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann. NY Acad. Sci. 505, 526–538 (1987).
   PubMed Web of Science ®Google Scholar
• Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin. Immunol. Immunopathol. 7(1), 36–43 (1977).
   PubMedGoogle Scholar
• Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11), 1054–1059 (1976).
   PubMed Web of Science ®Google Scholar
• Lefvert AK, Bergström K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J. Neurol. Neurosurg. Psychiatr. 41(5), 394–403 (1978).
   PubMed Web of Science ®Google Scholar
• Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J. Neurol. Neurosurg. Psychiatr. 48(12), 1246–1252 (1985).
   PubMed Web of Science ®Google Scholar
• Agius MA, Richman DP, Vincent A. Autoantibody testing in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related disorders. In: Myasthenia Gravis and Related Disorders (2nd Edition). Kaminski HJ (Ed.). Humana Press, NJ, USA, 143–156 (2009).
   Google Scholar
• Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin. Exp. Immunol. 49(2), 257–265 (1982).
   PubMed Web of Science ®Google Scholar
• Lefvert AK, Björkholm M. Antibodies against the acetylcholine receptor in hematologic disorders: implications for the development of myasthenia gravis after bone marrow grafting. N. Engl. J. Med. 317(3), 170 (1987).
   PubMedGoogle Scholar
• Lennon VA. Serological diagnosis of myasthenia gravis and Lambert–Eaton myasthenic syndrome. In: Handbook of Myasthenia Gravis and Myasthenic Syndromes. Lisak RP (Ed.). Marcel Dekker, NY, USA, 149–164 (1994).
   Google Scholar
• McKeon A, Lennon VA, Jacob A et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39(1), 87–90 (2009).
   PubMed Web of Science ®Google Scholar
• Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 36(5), 651–658 (2007).
   PubMed Web of Science ®Google Scholar
• Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin. Cancer Res. 10(21), 7270–7275 (2004).
   PubMed Web of Science ®Google Scholar
• Tindall RS. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann. Neurol. 10(5), 437–447 (1981).
   PubMed Web of Science ®Google Scholar
• Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1), 16–23 (2000).
   PubMed Web of Science ®Google Scholar
• Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33(10), 1316–1321 (1983).
   PubMed Web of Science ®Google Scholar
• Oosterhuis HJ, Limburg PC, Hummel-Tappel E, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J. Neurol. Sci. 58(3), 371–385 (1983).
   PubMed Web of Science ®Google Scholar
• Oosterhuis HJ, Limburg PC, Hummel-Tappel E, Van den Burg W, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy. J. Neurol. Sci. 69(3), 335–343 (1985).
   PubMed Web of Science ®Google Scholar
• Tindall RS. Humoral immunity in myasthenia gravis: effect of steroids and thymectomy. Neurology 30(5), 554–557 (1980).
   PubMed Web of Science ®Google Scholar
• Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 33(10), 1276–1282 (1983).
   PubMed Web of Science ®Google Scholar
• Zong Y, Zhang B, Gu S et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev. 26(3), 247–258 (2012).
   PubMed Web of Science ®Google Scholar
• Punga AR, Lin S, Oliveri F, Meinen S, Rüegg MA. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp. Neurol. 230(2), 207–217 (2011).
   PubMed Web of Science ®Google Scholar
• Shiraishi H, Motomura M, Yoshimura T et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57(2), 289–293 (2005).
   PubMed Web of Science ®Google Scholar
• Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 63(6), 782–789 (2008).
   PubMed Web of Science ®Google Scholar
• Shigemoto K, Kubo S, Maruyama N et al. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116(4), 1016–1024 (2006).
   PubMed Web of Science ®Google Scholar
• Jha S, Xu K, Maruta T et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175(1–2), 107–117 (2006).
   PubMed Web of Science ®Google Scholar
• ter Beek WP, Martínez-Martínez P, Losen M et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am. J. Pathol. 175(4), 1536–1544 (2009).
   PubMed Web of Science ®Google Scholar
• Lavrnic D, Losen M, Vujic A et al. The features of myasthenia gravis with autoantibodies to MuSK. J. Neurol. Neurosurg. Psychiatr. 76(8), 1099–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Mori S, Kubo S, Akiyoshi T et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 180(2), 798–810 (2012).
   PubMed Web of Science ®Google Scholar
• Mori S, Yamada S, Kubo S et al. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J. Neuroimmunol. 244(1–2), 1–7 (2012).
   PubMed Web of Science ®Google Scholar
• Klooster R, Plomp JJ, Huijbers MG et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135(Pt 4), 1081–1101 (2012).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Ito M, Hirayama M et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77(20), 1819–1826 (2011).
   PubMed Web of Science ®Google Scholar
• Hatanaka Y, Hemmi S, Morgan MB et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 65(9), 1508–1509 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu D, Yang Z, Luo Z, Luo S, Xiong WC, Mei L. Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. J. Neurosci. 28(7), 1688–1696 (2008).
   PubMed Web of Science ®Google Scholar
• Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44(1), 36–40 (2011).
   PubMed Web of Science ®Google Scholar
• Evoli A, Tonali PA, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126(Pt 10), 2304–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Ohta K, Shigemoto K, Kubo S et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 62(11), 2132–2133 (2004).
   PubMed Web of Science ®Google Scholar
• Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60(12), 1978–1980 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J. Neuroimmunol. 230(1–2), 148–152 (2011).
   PubMed Web of Science ®Google Scholar
• Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J. Neuroimmunol. 201–202, 85–89 (2008).
   PubMed Web of Science ®Google Scholar
• Leite MI, Ströbel P, Jones M et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann. Neurol. 57(3), 444–448 (2005).
   PubMed Web of Science ®Google Scholar
• Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67(3), 505–507 (2006).
   PubMed Web of Science ®Google Scholar
• Niks EH, van Leeuwen Y, Leite MI et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J. Neuroimmunol. 195(1–2), 151–156 (2008).
   PubMed Web of Science ®Google Scholar
• Strauss AJ, Kemp PG Jr. Serum autoantibodies in myasthenia gravis and thymoma: selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J. Immunol. 99(5), 945–953 (1967).
   PubMed Web of Science ®Google Scholar
• Marx A, Willcox N, Leite MI et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 43(5–6), 413–427 (2010).
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur. J. Neurol. 9(1), 55–61 (2002).
   PubMed Web of Science ®Google Scholar
• Wang K, McClure J, Tu A. Titin: major myofibrillar components of striated muscle. Proc. Natl Acad. Sci. USA 76(8), 3698–3702 (1979).
   PubMed Web of Science ®Google Scholar
• Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch. Neurol. 58(6), 885–890 (2001).
   PubMed Web of Science ®Google Scholar
• Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch. Neurol. 57(11), 1596–1600 (2000).
   PubMedGoogle Scholar
• Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20(2), 99–104 (1995).
   PubMed Web of Science ®Google Scholar
• Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J. Neuroimmunol. 111(1–2), 169–176 (2000).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Aarli JA, Matre R et al. Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. Eur. J. Neurol. 4, 131–137 (1997).
   PubMed Web of Science ®Google Scholar
• Romi F, Bø L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J. Neuroimmunol. 128(1–2), 82–89 (2002).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Freiburg A, Kolmerer B et al. Titin transcripts in thymomas. J. Autoimmun. 10(6), 551–557 (1997).
   PubMed Web of Science ®Google Scholar
• Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am. J. Physiol. 266(6 Pt 1), C1485–C1504 (1994).
   PubMed Web of Science ®Google Scholar
• Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 57(7), 843–846 (1994).
   PubMed Web of Science ®Google Scholar
• Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur. J. Neurol. 14(6), 617–620 (2007).
   PubMed Web of Science ®Google Scholar
• Mygland A, Tysnes OB, Aarli JA, Matre R, Gilhus NE. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. J. Autoimmun. 6(4), 507–515 (1993).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve 27(1), 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Mygland A, Tysnes OB, Matre R, Aarli JA, Gilhus NE. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 17(4), 327–331 (1994).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Muscle Nerve 21(3), 329–335 (1998).
   PubMed Web of Science ®Google Scholar
• Ohta M, Ohta K, Itoh N, Kurobe M, Hayashi K, Nishitani H. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a western blotting analysis. Clin. Chim. Acta 187(3), 255–264 (1990).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Sato T, Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology 37(8), 1329–1333 (1987).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur. J. Neurol. 15(10), 1029–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Yoshikawa H et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66(11), 1334–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011, 740583 (2011).
   PubMedGoogle Scholar
• Suzuki S, Satoh T, Yasuoka H et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J. Neuroimmunol. 170(1–2), 141–149 (2005).
   PubMed Web of Science ®Google Scholar
• Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J. Neurol. 259(7), 1312–1316 (2011).
   PubMed Web of Science ®Google Scholar
• Agius MA, Zhu S, Kirvan CA et al. Rapsyn antibodies in myasthenia gravis. Ann. NY Acad. Sci. 841, 516–521 (1998).
   PubMed Web of Science ®Google Scholar
• Agius MA, Zhu S, Aarli JA. Antirapsyn antibodies occur commonly in patients with lupus. Ann. NY Acad. Sci. 841, 525–526 (1998).
   PubMed Web of Science ®Google Scholar
• Phillips TM, Manz HJ, Smith FA, Jaffe HA, Cohan SL. The detection of anti-cholinesterase antibodies in myasthenia gravis. Ann. NY Acad. Sci. 377, 360–371 (1981).
   PubMed Web of Science ®Google Scholar
• Geen J, Howells RC, Ludgate M, Hullin DA, Hogg SI. The prevalence of anti-acetylcholinesterase antibodies in autoimmune disease. Autoimmunity 37(8), 579–585 (2004).
   PubMed Web of Science ®Google Scholar
• Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69(2), 418–422 (2011).
   PubMed Web of Science ®Google Scholar
• Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259(3), 427–435 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69(4), 445–451 (2012).
   PubMed Web of Science ®Google Scholar
• Yang L, Maxwell S, Leite MI et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J. Neurol. Sci. 301(1–2), 71–76 (2011).
   PubMed Web of Science ®Google Scholar
• Papp K, Prechl J. The use of antigen microarrays in antibody profiling. Methods Mol. Biol. 815, 175–185 (2012).
   PubMedGoogle Scholar